2024 SABCS
2024年圣安东尼奥乳腺癌学术研讨会（SABCS）将于2024年12月10至13日在美国德克萨斯州圣安东尼奥举行。SABCS官网已披露入选本次大会的摘要标题，医脉通小编为您汇总大会相关信息，精选中国专家报告内容，往期传送：
本期将继续为读者带来Poster Session 2（壁报展示2）部分，医脉通与您携手同行，共同探索前沿医学成果！
医脉通小编与您相约圣安东尼奥Henry B. Gonzalez会议中心（地址：900 E. Market Street, San Antonio, TX 78205 USA），为您带来一手资讯！敬请关注医脉通乳腺肿瘤，共享乳腺癌领域最新进展！
Henry B. Gonzalez Convention Center
中国专家壁报展示专场日期及时间一览，跟随医脉通，共享学术盛宴！
General Session与Poster Spotlight Sessions时间轴
Poster Session 2
壁报展示2
当地时间：2024/12/11 17:30-19:00
北京时间：2024/12/12 7:30-9:00
位置：Halls 2-3
01
P2-01-23
A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC
140基因机器学习分类器预测2500例TNBC患者的生存率和对化疗和免疫治疗的反应
报告人：Xixuan Zhu
02
P2-02-09
Novel Intramolecular BRCT Domain Interaction with ECT2 C-terminal Intramolecular Interaction Domain Regulates GEF
新型分子内BRCT结构域与ECT2 C末端分子内相互作用结构域调节GEF活性和肿瘤发生
报告人：Jinyu Lu
03
P2-02-11
Unveiling the subtype-specific role of PTPRK in triple-negative breast cancer: Implications for targeted therapies
揭示PTPRK在三阴性乳腺癌中的亚型特异性作用：对靶向治疗的影响
报告人：Xiangyi Liu
04
P2-02-14
C1QL1 inhibits breast cancer through HSP90α/VCP-ERS/UPR axis
C1QL1通过HSP90α/VCP-ERS/UPR轴抑制乳腺癌
报告人：Ningning Zhang
05
P2-02-15
Engineered macrophages secreting TRAIL achieve immunotherapy for triple-negative breast cancer by inhibiting the Wnt/β-catenin signaling pathway
分泌TRAIL的工程巨噬细胞通过抑制Wnt/β-catenin信号通路实现对三阴性乳腺癌的免疫治疗
报告人：宋传贵
06
P2-02-19
Virtual Multiplex Immunofluorescence Identifies Lymphocyte Subsets Predictive of Response to Neoadjuvant Therapy
虚拟多重免疫荧光识别预测新辅助治疗反应的淋巴细胞亚群
报告人：Anran Li
07
P2-02-20
Prediction of Axillary Lymph Node Metastasis in Breast Cancer using Intraoperative Fluorescence Multi-modal Imaging
使用术中荧光多模态成像预测乳腺癌腋窝淋巴结转移
报告人：He Sun
08
P2-03-17
Targeting NR2F2 overcomes multiple forms of endocrine resistance
靶向NR2F2可克服多种形式的内分泌抵抗
报告人：Yanyan Cai
09
P2-03-18
Lymph node metastasis of breast cancer: subclonal selection for high lipid metabolism from the primary tumor
乳腺癌淋巴结转移：原发肿瘤高脂质代谢的亚克隆选择
报告人：Yue Zhou
10
P2-04-02
TRIB3 regulates lipophagy and drives the metastasis of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway
TRIB3通过激活PI3K/AKT/mTOR通路调节脂肪吞噬并驱动三阴性乳腺癌的转移
报告人：zirong jiang
11
P2-04-04
Integrated stress response-upregulated mitochondrial SLC1A5var enhances glucose dependency of human breast cancer cells
综合应激反应上调线粒体SLC1A5var增强人乳腺癌细胞的葡萄糖依赖性
报告人：Sheng-Fan Wang
12
P2-04-07
Dual function of PRAK in TP53-associated breast cancer metastasis
PRAK在TP53相关乳腺癌转移中的双重功能
报告人：Jingjing Liu
13
P2-04-08
Functions of KLF5 in the cell cycle and breast cancer cell proliferation
KLF5在细胞周期和乳腺癌细胞增殖中的功能
报告人：Xiaoyun Mao
14
P2-04-09
A Novel Role of IP6K2 in Regulating Host Cell Death through p21-mediated cell cycle arrest during HSV-1 oncolytic virus Therapy
在HSV-1溶瘤病毒治疗期间，IP6K2通过p21介导的细胞周期停滞在调节宿主细胞死亡中的新作用
报告人：Zhijian Huang
15
P2-04-10
ARL3 Promotes Hormone Receptor Positive Breast Cancer Progression and Tamoxifen Resistance through ERαStablization
ARL3通过ERα稳定促进激素受体阳性乳腺癌进展和他莫昔芬耐药
报告人：Han Li
16
P2-04-11
Selective Pre-clinical Targeting of CD44+ ADAR1+ Triple Negative Breast Cancer
CD44+ ADAR1+ 三阴性乳腺癌的选择性临床前靶向
报告人：Wenxue Ma
17
P2-04-12
JAM A expression and its clinical/prognostic value in breast cancer
JAM表达及其在乳腺癌中的临床预后价值
报告人：Yufei Lou
18
P2-04-19
Identification and Validation of Novel Necroptosis-Related lncRNAs for Prognostic Prediction in Breast Cancer
鉴定和验证新型坏死性凋亡相关lncRNAs对乳腺癌预后预测的作用
报告人：Zhijian Huang
19
P2-04-25
Different Pyroptosis Phenotype within Breast Cancer Possess Distinctive Prognosis and Tumor Immune Microenvironment
乳腺癌内不同的焦亡表型具有独特的预后和肿瘤免疫微环境
报告人：Ye Hong
20
P2-04-26
Predicting the prognosis and immunotherapeutic response of triple-negative breast cancer by constructing a prognostic model based on CD8T cell-related immune genes
通过构建基于CD8T细胞相关免疫基因的预后模型来预测三阴性乳腺癌的预后和免疫治疗反应
报告人：Zhijian Huang
21
P2-04-29
Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning: A SEER population-based study
基于机器学习的乳腺浸润性微状癌预后指数预测模型：一项基于SEER人群的研究
报告人：zirong jiang
22
P2-04-30
Harnessing Technology: A Comparative Study of AI versus Manual Scoring in HER2 Ultra-low Breast Cancer
利用技术：AI与手动评分在HER2超低表达乳腺癌中的比较研究
报告人：Xu Xuan Lim
23
P2-05-10
Depression and anxiety in patients with breast cancer receiving radiotherapy: A prospective longitudinal study
接受放疗的乳腺癌患者的抑郁和焦虑：一项前瞻性纵向研究
报告人：Shi-Jia Wang
24
P2-05-11
A prospective cohort study of real-world patient-reported outcomes in HER2-positive early breast cancer patients receiving (neo) adjuvant anti-HER2 based therapy: the preliminary results at 2-cycle treatment
接受（新）辅助抗HER2治疗的早期乳腺癌患者真实世界患者报告结果的前瞻性队列研究：2周期治疗的初步结果
报告人：余科达
25
P2-05-19
An ICG-labeled Novel Trop2 Targeting Peptide for In Vivo and Ex Vivo NIR-II Fluorescence Imaging-guided Breast Cancer Precise Surgery
一种ICG标记的新型Trop2靶向肽，用于体内和离体NIR-II荧光成像引导的乳腺癌精准手术
报告人：Kangliang Lou
26
P2-05-25
Comparative Study of Droplet-digital PCR and Ultra-sensitive NGS Assay for ctDNA Profiling in Breast Cancer
液滴式数字PCR和超灵敏NGS检测在乳腺癌中ctDNA分析的比较研究
报告人：Binggang Xiang, Jie Zhang
27
P2-05-27
Revealing prognostic subtypes and related model of early-stage TNBC
揭示早期TNBC的预后亚型和相关模型
报告人：傅佩芬
28
P2-06-01
CBP/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in TNBC
CBP/P300溴结构域抑制可减少TNBC中中性粒细胞的积累并激活抗肿瘤免疫
报告人：Xueying Yuan
29
P2-06-12
MGAT1-Mediated Glycosylation Orchestrates Immune Checkpoints and Antitumor Immunity
MGAT1介导的糖基化协调免疫检查点和抗肿瘤免疫
报告人：Junlong Chi
30
P2-06-14
Calcium-Sensing Receptor Agonist Enhanced Anti-Tumor Activity of Adoptive NK Cell Therapy in Triple-Negative Breast Cancer
钙敏感受体激动剂增强过继性NK细胞疗法在三阴性乳腺癌中的抗肿瘤活性
报告人：Yu Shi
31
P2-06-23
Using a Machine Learning Model for Prediction of Palbociclib Response in a Single Institution, Real-World Analysis of Patients with ER+ HER2- Advanced Breast Cancer
使用机器学习模型预测单个机构中的哌柏西利反应，对ER+ HER2-晚期乳腺癌患者进行真实世界分析
报告人：Xiaojie Zhang
32
P2-07-03
Noninvasive imaging of breast cancer and metastasis using TROP2-targeting radiotracer 68Ga-TTP
使用TROP2靶向放射性示踪剂68Ga-TTP对乳腺癌和转移进行无创成像
报告人：Yifei Pei
33
P2-07-14
Head-to-head comparison of the dual-targeting tracer [68Ga]Ga-RM26-RGD and [18F]FDG for PET imaging of breast cancer
双靶向示踪剂[68Ga]Ga-RM26-RGD和[18F]FDG用于乳腺癌PET成像的头对头比较
报告人：Qingyao Shang
34
P2-07-27
Long-term administration of endocrine therapy on the gut microbiota of breast cancer patients between disease-free and recurrence
在无病和复发之间对乳腺癌患者的肠道微生物群长期进行内分泌治疗
报告人：Ming-Feng Hou
35
P2-07-28
A New Option for post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6 Inhibitors
后CDK4/6is耐药时代的新选择：基于安罗替尼的联合治疗对CDK4/6抑制剂耐药的激素受体阳性转移性乳腺癌的多中心真实世界研究
报告人：欧阳取长
36
P2-08-13
Effectiveness of Combined Neoadjuvant Pembrolizumab and Chemotherapy in Early Triple-Negative Breast Cancer: Real-World Evidence from Multiple Centers in Asia
新辅助帕博利珠单抗联合化疗在早期三阴性乳腺癌中的疗效：来自亚洲多个中心的真实世界证据
报告人：Yu-Ting Lin
37
P2-09-08
Correlating Breast Density with FDG-avidity on PET Imaging
PET成像上乳腺密度与FDG-avidity的相关性
报告人：YiLi Zhao
38
P2-09-11
Improved Prediction of Axillary Lymph Node Metastasis in Early-Stage Breast Cancer Using Deep Learning on Routine Mammography
使用常规乳腺X线摄影深度学习改进对早期乳腺癌腋窝淋巴结转移的预测
报告人：Daqu Zhang
39
P2-09-17
Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/HER2- advanced breast cancer: the Linux trial
CDK4/6抑制剂中多组学相似性网络融合（SNF）亚型的精准医学HR+/HER2-晚期乳腺癌失败：Linux试验
报告人：Lei Fan
40
P2-09-28
Dalpiciclib plus endocrine therapy for visceral crisis in advanced breast cancer: a multicenter, prospective, external controlled phase 2 study
达尔西利联合内分泌治疗晚期乳腺癌内脏危象：一项多中心、前瞻性、外部对照的II期研究
报告人：Hongnan Mo
41
P2-10-01
Real-world Experience with CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic and Recurrent Breast Cancer in Asian Population
CDK4/6抑制剂在亚洲人群激素受体阳性转移性和复发性乳腺癌中的真实世界经验
报告人：Bo-Fang Chen
42
P2-10-08
The Impact of Time-to-Surgery (TTS) for Breast Cancer Prognosis After Neoadjuvant Chemotherapy
手术时间（TTS）对新辅助化疗后乳腺癌预后的影响
报告人：Xin Wang
43
P2-10-13
The Real World Practice of Prospectively Breast Cancer Screening Program for High Polygenic Risk Score Population in Taiwan
台湾省多基因高风险人群乳腺癌前瞻性筛查计划的现实实践
报告人：Yu-Wen Weng
44
P2-10-16
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT)
瑜伽治疗化疗引起的周围神经病变（YCT）III期随机临床试验
报告人：Ting Bao
45
P2-11-01
Comprehensive spatially resolved single-cell analysis of immunotypes in triple-negative breast cancer revealed the central role of intratumoral MHC class II expressions
对三阴性乳腺癌免疫分型的全面空间分辨单细胞分析揭示了瘤内MHC II类表达的核心作用
报告人：Yi Liu
46
P2-11-06
Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial
局部晚期免疫调节性三阴性乳腺癌患者的新辅助化疗加卡瑞利珠单抗与化疗：一项前瞻性、随机、开放标签的II期试验
报告人：Li Chen
47
P2-11-13
Retrospective validation of digital twin-based prediction of personalized triple negative breast cancer response to neoadjuvant therapy regimens
基于数字孪生的个性化三阴性乳腺癌对新辅助治疗方案反应预测的回顾性验证
报告人：Chengyue Wu
48
P2-12-22
A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer.
口服CDK4/6抑制剂darciclib联合内分泌治疗辅助治疗激素受体阳性、HER2阴性女性乳腺癌的多中心、单臂、II期临床试验。
报告人：Jie Ouyang
49
P2-12-30
A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy treatment (ACT)
针灸治疗化疗引起的周围神经病变（ACT）的随机III期临床试验
报告人：Ting Bao
备注：排名不分先后，按照摘要号进行排序。本文内容基于SABCS官网发布的信息整理，因目前壁报部分未公布报告者单位，信息可能有遗漏或错误，欢迎留言告知。
编辑：KIKI
审校：Uni/Ryland
排版：KIKI
执行：Squid
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。
